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Abstract
Background: Helicobacter pylori is the main risk factor for the development of non-cardia gastric
cancer. Increased proliferation of the gastric mucosa is a feature of H. pylori infection. Mucosal
interkeukin-1β  production is increased in H. pylori infection and IL-1β  genotypes associated with
increased pro-inflammatory activity are risk factors for the development of gastric cancer. The
effect of IL-1β  on gastric epithelial cell proliferation has been examined in this study.
Methods: AGS cells were cultured with IL-1β . DNA synthesis was assed by [3H]thymidine
incorporation and total viable cell numbers by MTT assay.
Results: IL-1β  dose dependently increased DNA synthesis and cell numbers. The enhanced
proliferation was blocked by interleukin-1 receptor antagonist. Addition of neutralising antibody to
GM-CSF reduced IL-1β -stimulated proliferation by 31 ± 4 %. GM-CSF alone significantly stimulated
proliferation. Addition or neutralisation of IL-8 had no effect on basal or IL-1β -stimulated
proliferation. The tyrosine kinase inhibitor genistein completely blocked IL-1β -stimulated
proliferation and inhibition of the extracellular signal related kinase pathway with PD 98059
inhibited IL-1β  stimulated proliferation by 58 ± 5 %.
Conclusions: IL-1β  stimulates proliferation in gastric epithelial cells. Autocrine stimulation by GM-
CSF contributes to this proliferative response. Signalling via tyrosine kinase activity is essential to
the mitogenic response to IL-1β . The extracellular signal related kinase pathway is involved in, but
not essential to downstream signalling. IL-1β  may contribute to the hyperproliferation seen in H.
pylori- infected gastric mucosa, and be involved in the carcinogenic process.
Background
Helicobacter pylori is believed to be the major aetiological
factor in the development of non-cardia gastric adenocar-
cinoma. Large-scale epidemiological studies have con-
firmed a strong association between H. pylori infection
and both cancer [1–3] and the earlier histological stages,
atrophy and intestinal metaplasia [4,5]; both of which in-
crease the risk of later neoplastic transformation. Animal
models have also demonstrated the importance of H. py-
lori in gastric carcinogenesis [6,7]. Increased rates of pro-
liferation of the gastric mucosa are typical in H. pylori
infection [8–11], and hyperproliferation within the gas-
trointestinal tract appears to be a marker for later malig-
nant change [12]. The cause of the increased rate of
proliferation is not clear, but the increased rates reduce to
normal with clearance of the infection [8,13]. Although
hypeprproliferation is typical in vivo, studies testing the ef-
fects of H. pylori or its products in vitro have shown con-
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flicting results, with both enhanced [14,15] and
diminished [16–18] proliferation reported. It is possible
that other components of the inflammatory response typ-
ical of H. pylori infected mucosa could be at least partly re-
sponsible for driving the increased cell proliferation.
The pluripotent pro-inflammatory cytokine interleukin-
1β  has a central role in the pathogenesis of H. pylori-in-
duced mucosal inflammation. IL-1β  gene expression and
protein production are increased in H. pylori infection and
reduce with successful eradication [19,20]. The presence
of the IL-1β  genotype polymorphism associated with en-
hanced IL-1β -production has been associated with a sig-
nificant increased risk of gastric cancer and pre-cancerous
lesions [21,22]. Interleukin-1β  is a potent inhibitor of gas-
tric acid secretion and it is hypothesized that the en-
hanced IL-1β  response alters the topography of the gastric
infection and thus promotes inflammation and subse-
quent atrophy of the gastric corpus [23,24]. The possibili-
ty that IL-1β  itself drives the increased proliferation of
gastric epithelial cells has not been fully investigated. Al-
teration of gastric proliferation by IL-1β  might contribute
to the carcinogenic process, in addition to effects on acid
secretion. Therefore the direct effects of IL-1β  on gastric
epithelial proliferation have been assessed.
The mitogen-activated protein kinase (MAPK) cascades
are well-characterised pathways transducing signals from
the cell surface to the nucleus. The family includes distinct
subgroups; extracellular signal-related kinases (ERKs), c-
Jun NH2-terminal kinases (JNKs) and p38 MAPK [25].
The ERKs are activated by a variety of extracellular stimuli,
and mediate the pro-proliferative effects of a number of
hormones and growth factors [26,27]. Activation by phos-
phorylation of a dual specificity protein kinase (MAP ki-
nase kinase (MAPKK)), (also known as MEK), allows it in
turn to activate a family of serine-threonine protein kinas-
es, known as the ERKs. The ERKs in turn phosphorylate
numerous cellular proteins including transcription factors
and thus have a central role in propagation of mitogenic
signals. Accordingly the role of the MAP-kinase pathway
in mediating the responses to IL-1β  has been assessed.
Methods
Cell culture
The human AGS gastric carcinoma cell line was purchased
from the European Collection of Animal Cell Cultures
(Porton Down, UK). Cells were grown in monolayer cul-
ture in RPMI 1640 medium supplemented with 100 µg/
ml penicillin, 100 µg/ml streptomycin, 100 µg/ml gen-
tamicin, 2.5 µg/ml amphoteracin B and 10 % foetal calf
serum. Cells were grown in 75 cm2 tissue culture flasks at
37°C in an atmosphere of 5% CO2 and 95% air and pas-
saged every 5–7 days.
Proliferation studies
[3H]thymidine incorporation. Cells were grown in media
containing 10% foetal calf serum, plated into 24-well
plates at 105 cells/well and allowed to attach overnight.
After washing with serum-free media, cells were incubated
in serum free medium containing 0.2 mM unlabelled thy-
midine for 24 hours in the presence of increasing concen-
trations of IL-1β , IL-8 or GM-CSF. DNA synthesis was
estimated by measurement of [3H]thymidine incorpora-
tion into the trichloroacetic acid (TCA) precipitable mate-
rial [28]. [3H]thymidine (0.1 µCi/ml, 10 Ci/mmol) was
added 2 hours before the end of a 24 hour treatment peri-
od. Cells were washed twice with serum-free medium to
remove unincorporated [3H]thymidine, and DNA was
precipitated with 5% TCA at 4°C for 15 minutes. The pre-
cipitates were then washed twice with 95% ethanol, dis-
solved in 1 ml of NaOH, and analysed by liquid
scintillation counting. Results are expressed as percent
control unstimulated [3H]thymidine incorporation
(mean  ± SD) of 4–6 different experiments, each per-
formed in triplicate. For the detection of growth inhibi-
tion, cells were incubated with either the specific MEK
inhibitor PD 98059 (25 µM)[29], IL-1 receptor antagonist
(500 ng/ml) [30] or the neutralising antibodies, anti-GM-
CSF (5 µg/ml) or anti-IL-8 (10 µg/ml). Inhibitors or anti-
bodies were added 30 minutes prior to cytokines.
Cell growth
Total viable cell numbers were assessed by a modified
MTT (3-[4,5-dimethylthiazol-2-yl]-2.5 diphenyl tetra-
zolim bromide assay) [31]. Cells were plated into 24-well
plates in medium containing 10% foetal calf serum. After
attachment overnight, the medium was changed to 1%
foetal calf serum-supplemented medium and increasing
concentrations of IL-1β  were added. Cells were cultured
for 48 hours and then the medium was removed and fresh
RPMI 1640 medium containing 0.5 ng/ml MTT was add-
ed. Cells were incubated at 37°C for 3 hours. The medium
was then removed and 0.04 M HCl in isopropanol was
added to extract the reduced formazan product. The re-
sulting optical density at 550 nm was determined.
Chemicals and reagents
Recombinant human IL-1β  and IL-8 were purchased from
Sigma (Poole, UK), recombinant human GM-CSF and IL-
1 receptor antagonist, anti-GM-CSF and anti-IL-8 were
from R and D systems (Abingdon, Uk). PD 95059 was
from Calbiochem (Nottingham, UK). RPMI 1640 was
from Gibco BRL (Paisley, UK) and all other reagents were
from Sigma. Concentrations of inhibitors used were taken
from manufacturers' data and published data. The ability
of 500 ng/ml IL-1RA to abolish 10 ng/ml IL-1β -stimula-
tion of IL-8 secretion in AGS cells was confirmed. The ef-
ficacy of the anti-GM-CSF at 5 µg/ml antibody to abolishBMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/7
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GM-CSF (1 ng/ml) induced AGS cell proliferation was
confirmed.
Statistics
Cytokine-stimulated results where compared with control
unstimulated cells on the same 24-well plate. Data were
compared by one-way analysis of variance and Student's
t-test to determine statistical significance. Each experi-
ment as performed in triplicate on 4–6 occasions. Results
are expressed as mean ± standard deviation. Differences
with P values of < 0.05 were considered significant.
Results
Effect of IL-1β  on [3H]thymidine incorporation
Interleukin-1β  caused a dose-dependent increase in DNA
synthesis as measured by thymidine incorporation. As
shown in figure 1, significant stimulation was seen with
1–100 ng/ml IL-1β . The maximal stimulation of 52 ± 6 %
above control was seen with 10 ng/ml. The higher dose of
100 mg/ml was slightly less effective in stimulating prolif-
eration.
Effect of IL-1β  on cell number
The increase in DNA synthesis by IL-1β  was translated
into an absolute increase in viable cell numbers. As shown
in figure 2, IL-1β  increased cell numbers in a dose-de-
pendent manner similar to the effects on [3H]thymidine
incorporation. The maximal stimulation was again seen at
10 ng/ml of IL-1β , which produced a 22 ± 5 % increase in
total cell number.
Effects of cytokine inhibition or receptor antagonism on 
IL-1β -stimulation of proliferation
Pretreatment of the cells with interleukin-1 receptor an-
tagonist abolished the stimulatory effects of IL-1β  on
[3H]thymidine incorporation (Figure 3). Previous studies
have shown that IL-1β  can activate gastric epithelial cells,
including AGS cells, to secrete other cytokines, particular-
ly interleukin-8 and granulocyte-macrophage colony
stimulating factor (GM-CSF)[31,32]. Therefore further
studies were undertaken to assess if the stimulatory ac-
tions of IL-1β  were mediated by either of these two cy-
tokines. Neutralising antibodies to either IL-8 or GM-CSF
had no effect on unstimulated [3H]thymidine incorpora-
tion. Neutralisation of IL-8 had no effect on IL-1β -
stimuated growth but the anti-GM-CSF antibody reduced
IL-1β -stimulated proliferation by 31 ± 4 % (P < 0.01) (fig-
ure 3).
Effects of GM-CSF on proliferation
In view of the results obtained with the anti-GM-SCF an-
tibody, the direct growth-stimulatory actions of GM-CSF
were examined. GM-CSF had a potent growth stimulatory
action on AGS cells: significant enhancement of [3H]thy-
midine incorporation was seen at all concentrations
(0.001–100 ng/ml) of GM-CSF. GM-CSF itself appeared
to be a more potent stimulant than IL-1β  ; maximal stim-
ulation of 108 ± 17 % above control was seen with 100
ng/ml of GM-CSF (Figure 4). The inhibitory action of the
anti-GM-CSF antibody was confirmed by abolition of the
growth stimulatory action of 1 ng/ml GM-CSF (data not
shown). Previous studies have shown that IL-1β -stimulat-
ed GM-CSF release under similar conditions in AGS cells
to be approximately 10–20 pg/well/24 hours [32]. To
confirm the results obtained with the anti-IL-8 antibody,
[3H]thymidine incorporation was measured in response
to IL-8. No enhancement of proliferation was seen at any
concentration of IL-8 (0.001–100 ng/ml) (data not
Figure 1
Effect of IL-1β  on [3H]thymidine incorporation into gastric
epithelial AGS cells Cells were treated with increasing con-
centrations of IL-1β  for 24 hours and DNA synthesis
assessed by [3H]thymidine incorporation. Results expressed
as means ± standard deviation. *P < 0.01 vs. control
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Figure 2
Effect of IL-1β  on cell numbers of gastric epithelial cells Cells
were treated with increasing concentrations of IL-1β  for 48
hours and total viable cell numbers assessed by MTT assay.
Results expressed as means ± standard deviation. *P < 0.01
vs. control
*
*
*
[IL-1E] /(ng/ml)
80
100
120
140
control 0.1 1 10 100
80
100
120
140
control 0.1 1 10 100
c
e
l
l
 
n
u
m
b
e
r
 
/
 
(
%
 
c
o
n
t
r
o
l
)
*
*
*BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/7
Page 4 of 8
(page number not for citation purposes)
shown). Under similar conditions IL-1β -stimulated IL-8
release is approximately 3000 pg/well/24 hours [31].
Mechanism of IL-1β -stimulation of cell proliferation
The specific inhibitors genistein, which inhibits tyrosine
kinases and PD 98059, which inhibits MAP kinase kinase
(MEK), and thus inhibits the ERK-pathway, were used to
assess the possible intracellular pathways mediating the
effects of IL-1β . In order to examine the effects of IL-1β
distinct from those of GM-CSF, these experiments were
performed in the presence of the anti-GM-CSF neutralis-
ing antibody. As shown in figure 5, neither genistein nor
PD 98059 altered unstimulated [3H]thymidine incorpo-
ration. Genistein completely abolished the IL-1β -stimula-
tion of proliferation. Inhibition of MEK with PD 98059
reduced IL-1β -stimulated proliferation by 58 ± 5% (P <
0.01) (figure 5) but did not completely abolish the growth
stimulatory action of IL-1β . Further increases to supra-
maximal concentrations of PD 98050 did not further in-
hibit IL-1β -stimulated proliferation (data not shown).
Discussion
This study demonstrated that IL-1β  increased prolifera-
tion of AGS cells. This effect was reversed by the receptor
antagonist, suggesting it was mediated via the interleukin-
1 receptor. IL-1β  stimulated both [3H]thymidine incorpo-
ration, as a measure of stimulation of DNA synthetic rate
and also total cell numbers as measured by the MTT assay.
This illustrates that the stimulation of DNA synthesis by
IL-1β  is translated into a real increase in cell numbers.
A portion of the stimulatory action of IL-1β  appears to be
indirect. Neutralisation of GM-CSF in the media led to a
significant reduction of IL-1β -stimulated proliferation.
AGS cells are known to secrete GM-CSF in response to IL-
1β  [32]. GM-CSF itself was a potent stimulant of cell pro-
liferation. Thus it seems likely that part of the growth
stimulatory actions of IL-1β  are due to an autocrine inter-
Figure 3
Effect of cytokine inhibition on IL-1β -stimulation of [3H]thy-
midine into gastric epithelial cells AGS cells were treated
with 10 ng/ml IL-1β  for 24 hours plus either interleukin-1
receptor antagonist (IL-1RA 500 ng/ml), neutralising anti-IL-8
antibody (10 µg/ml) or neutralising anti-GM-CSF antibody (5
µg/ml). DNA synthesis was assessed by [3H]thymidine incor-
poration. Results expressed as means ± standard deviation.
*P < 0.01 vs. IL-1β  stimulation in absence of inhibitor.
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Figure 4
Effect of GM-CSF on proliferation of gastric epithelial cells.
AGS cells were treated with increasing concentrations of
GM-CSF for 24 hours. Cell proliferation was assessed by
[3H]thymidine incorporation. Results expressed as means ±
standard deviation. *P < 0.05, **P < 0.01 vs control
Figure 5
Effect of inhibition of tyrosine kinase and MEK activity on IL-
1β -stimulated gastric epithelial cell proliferation. AGS cells
were treated with 10 ng/ml IL-1β  for 24 hours in the pres-
ence of the tyrosine kinase inhibitor genistein (100 µM) or
the MEK inhibitor PD 98059 (25 µM). Proliferation was
assessed by [3H]thymidine incorporation. Studies were per-
formed in the presence of anti-GM-CSF antibody (5 µg/ml).
Results expressed as means ± standard deviation. *P < 0.01 vs
control
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mediary action of GM-CSF. There are limited previous
data suggesting that GM-CSF stimulates the proliferation
of non-haematopoietic cells; Dippold et al showed that
exogenous GM-CSF stimulated the growth of two out of
two cultures derived from gastric carcinomas and two out
of nine pancreatic carcinoma cell lines [33,34]. However,
unlike the current study, autocrine production of GM-CSF
was no detectable.
Gastric epithelial cells also produce IL-8 in response to IL-
1β  [31]. However in this model system, IL-8 alone had no
pro-proliferative action and neutralisation of IL-8 did not
affect the stimulatory action of IL-1β . Therefore it is un-
likely that IL-8 has an autocrine role in the growth-stimu-
latory action of IL-1β . It is possible that other cytokines
produced by the gastric epithelial cells in response to IL-
1β , H. pylori or other inflammatory insults could also play
a role as autocrine or paracrine mediators of growth. It has
recently been reported that another C-X-C chemokine,
GRO/CINC-1, which is also upregulated in H. pylori infec-
tion stimulated proliferation in rat gastric epithelial cells
[35]. The role of these other potential autocrine mediators
deserves further study.
The results of the inhibitor studies strongly suggest that ty-
rosine kinase activity is essential for the growth promoting
action of IL-1β  in AGS cells. The tyrosine kinase inhibitor
genistein abolished the stimulatory action of IL-1β . IL-1β
is known to activate a plethora of intracellular signalling
pathways [31,36–39], but in the current situation there
appears to be an absolute requirement for signalling via a
tyrosine kinase, subsequent on receptor activation.
The mitogen-activated protein cascade is a well-character-
ised pathway mediating the cell growth-stimulatory ac-
tions of many growth factors and hormones. Inhibition of
the ERK pathway, with the MEK inhibitor PD 98059,
which prevents activation of ERKs by phosphorylation,
had a significant inhibitory action against the stimulatory
action of IL-1β . This suggests that activation of the ERK
pathway is important in mediating the growth stimulato-
ry actions of IL-1β . Activation of MAP kinase cascades, in-
cluding the p42 and p44 ERK pathways and p46JNK and
p55JNK c-Jun NH2-terminal kinases by IL-1β  has been
demonstrated in rat gastric epithelial cells [41,42], but the
functional importance of these pathways was not exam-
ined. Activation of ERKs and JNKs was inhibited by genis-
tein [41], consistent with the inference of the current
study that MAPKs lie downstream of tyrosine activity in
IL-1β -induced signalling. However in the current study
PD 98059 did not completely abolish the stimulatory ac-
tion of IL-1β , suggesting that alternative pathways, activat-
ed subsequent on tyrosine kinase activity, also play a role
in the signalling of the proliferative responses to IL-1β .
Further studies are underway at present to examine these.
There are conflicting data available concerning the direct
effects of IL-1β  on gastric epithelial proliferation. Al-
though the current study and the study by Fan et al using
stimulated-leukocyte conditioned media showed in-
creased proliferation of the human AGS cell line [14], oth-
ers have shown inhibition of serum, TGF-α  and EGF-
stimulated proliferation in RGM1 rat gastric epithelial
cells by IL-1β  [41,42]. Tominaga et al showed that pre-
treatment of RGM1 cells with IL-1β  for 6 hours inhibited
proliferation at 24 hours, but the inhibitory effect was lost
at 48 hours, [41]. The reasons for these discrepancies are
not clear. They may reflect intrinsic differences between
the cell lines, differences in activation and involvement of
paracrine growth-promoting pathways, species variability,
an effect specific for certain growth factors, or underlying
differences in the biology of cell lines derived from cancer
(AGS) or normal tissue (RGM1). The studies demonstrat-
ing inhibition of proliferation by IL-1β  were performed in
the presence of powerful growth-promoting stimuli (high
serum or specific growth factor concentrations in the cul-
ture media), whist the current studies were performed in
serum-free or 1% serum media. It is possible that the mul-
tiple signalling pathways activated by IL-1β  have differing
effects on proliferation, the dominant effect depending on
the complex inter-relationships of stimuli and signalling
pathways under different circumstances. Pro-inflammato-
ry cytokines such as IL-1β  and TNF-α  activate different sig-
nalling pathways with divergent results and different
time-courses in gastric endocrine and parietal cells
[37,38,43–46]. Further studies are underway examining
the specific roles of the various signalling pathways in gas-
tric epithelial cells under different conditions.
There are now strong epidemiological data linking H. py-
lori with gastric carcinoma. The carcinogenic process ap-
pears to involve a number of steps: H. pylori-induced
inflammation progresses to atrophy, intestinal metapla-
sia, dysplasia and eventually carcinoma [47]. Similarly H.
pylori infection in Mongolian gerbils readily induces gas-
tric atrophy and cancer [6]. Whilst gastric carcinogenesis is
undoubtedly a multifactorial process, involving patho-
genic bacterial and host factors, including HLA status, diet
and antioxidant status [47,48], it is clear that increased
gastric epithelial proliferation, especially when relatively
increased compared to apoptosis, is an important part of
the pathway [49,50]. Increased gastric epithelial prolifera-
tion is typical of H. pylori infection; it is demonstrable
throughout all stages of the infection and eradication of
the infection reduces proliferation. Increased proliferation
is an important marker of increased risk of gastrointesti-
nal adenocarcinoma [12]. The mechanisms of the in-
creased proliferation are not completely understood. In
vitro studies testing cultures of H. pylori or constituents
have given conflicting results in different systems, with
different cell types and bacterial strains. Direct stimula-BMC Gastroenterology 2002, 2 http://www.biomedcentral.com/1471-230X/2/7
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tion of gastric epithelial proliferation by H. pylori has been
reported by some authors [14,15], whilst either neutral ef-
fects [15] or increased apoptosis and decreased prolifera-
tion have been reported by others [16–18]. Fan et al
reported that conditioned media from either H. pylori or
mitogen activated lymphocytes directly stimulated AGS
cell proliferation [14], suggesting that the inflammatory
response could be partly responsible for the enhancement
of epithelial proliferation. IL-1β  production is enhanced
in H. pylori infection and this cytokine is regarded as being
central to the regulation of the pro-inflammatory re-
sponse in H. pylori infection.
IL-1β  is a profound inhibitor of gastric acid secretion in vi-
vo[51] and in isolated parietal cells [37,38]. Genetic poly-
morphisms of the IL-1β  gene cluster causing increased
transcriptional activity are associated with an increased
risk of pre-cancerous and cancerous histological changes
in H. pylori infection [21,22]. The general hypothesis ex-
plaining this observation has been that enhanced IL-1β
production consequent on H. pylori infection is responsi-
ble for greater suppression of acid secretion, which in turn
allows greater colonisation of the acid-secreting body mu-
cosa [24]. This greater colonisation provokes further in-
flammation, which ultimately leads to loss of specialised
acid-secretory epithelium (atrophy) and further potenti-
ates the vicious cycle of increased inflammation and di-
minished acid secretion [52]. Gastric atrophy significantly
predisposes to cancer [3]. It is believed that atrophy in
combination with mediators released in inflammation
such as oxygen free radicals and nitric oxide, diet, anti-ox-
idant state and possibly bacterial overgrowth and genera-
tion of nitrosamines in the achlorhydric stomach [53]
advance the histological changes, cause mutageneisis and
drive progression to cancer.
An alternative, but not mutually exclusive, hypothesis is
that the enhanced cytokine response directly enhances ep-
ithelial cell proliferation and itself predisposes to cancer,
in addition to the effects on acid secretion. The increased
cell turnover of this hyperproliferative response would it-
self make the mucosa more vulnerable to the mutagenic
effects of free radicals and other toxic products generated
in the achlorhydric inflamed stomach.
Elsewhere in the gastrointestinal tract, IL-1β  has been
shown to stimulate [3H]thymidine incorporation and in-
crease cell number of cultured human colonic subepithe-
lial myofibroblasts, which is thought to have importance
in the remodelling of the mucosa in inflammation [54].
The pro-proliferative effects of IL-1β  in the gastrointesti-
nal tract deserve further study, given the importance of
this cytokine in the regulation of the mucosal inflamma-
tory response.
Conclusions
The results of the current study suggest that IL-1β  and GM-
CSF can directly stimulate gastric epithelial proliferation.
This might explain the proliferative responses to condi-
tioned lymphocyte media demonstrated by Fan et al[14].
Enhanced epithelial proliferation due to IL-1β  may con-
tribute to the enhanced risk of gastric cancer and precan-
cerous lesions in H. pylori-infected individuals with
specific IL-1β  alleles associated with higher levels of pro-
duction. IL-1β  stimulates proliferation via receptor-medi-
ated activation of a tyrosine kinase pathway. Downstream
signalling involves ERK-dependent and -independent
pathways.
Further studies will be necessary to clarify the mechanisms
involved in IL-1β -stimulation of gastric epithelial prolifer-
ation, as well as data correlating IL-1β  genotype, IL-1β
protein production and epithelial proliferation in vivo.
These will compliment the current study and further en-
hance our understanding of H. pylori-induced gastric car-
cinogenesis.
List of abbreviations
EGF – epidermal growth factor; ERK – extracellular signal
related kinase; GM-CSF – granulocyte-macrophage colony
stimulating factor; IL – interleukin; JNK – c-Jun NH2-ter-
minal kinase; MAP – mitogen activated protein; MTT – 3-
[4,5-dimethylthiazol-2-yl]-2.5 diphenyl tetrazolim bro-
mide; TCA – trichloroacetic acid; TGF-α  – transforming
growth factor alpha.
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